Table 1.

Consensus definitions from ASTCT by Kharfan-Dabaja et al. [17].

Term	Definition
Neutrophil recovery	Both panels endorsed the existing definition of neutrophil recovery as the first of 3 successive days with an absolute neutrophil count of ≥500/μL after post-transplantation nadir.
Platelet recovery	Both panels endorsed the definition of platelet recovery as the first of 3 consecutive days with a platelet count of 20,000/μL or higher in the absence of platelet transfusion for 7 consecutive days.
Graft rejection versus graft failure	Both panels defined graft rejection as an immune-mediated process, whereas graft failure represents a wider array of possibilities, including cell dosing, disease, infection, drugs, and an immune-mediated event.
Graft failure (primary)* (according to cell Source)	PBSCs: Both panels defined graft failure as lack of achievement of an ANC ≥500/μL by day +30 with associated pancytopenia.
	Unstimulated BM: Both panels defined graft failure as lack of achievement of an ANC ≥500/μL by day +30 with associated pancytopenia.
	UCB: Both panels defined graft failure as lack of achievement of an ANC ≥500/μL by day +42 with associated pancytopenia.
Poor graft function**	Both panels defined poor graft function as frequent dependence on blood and/or platelet transfusions and/or growth factor support in the absence of other explanations, such as disease relapse, drugs, or infections
Secondary graft failure*	Both panels defined secondary graft failure as a decline in hematopoietic function (may involve hemoglobin and/or platelets and/or neutrophils) necessitating blood products or growth factor support, after having met the standard definition of hematopoietic (neutrophils and platelets) recovery
Donor chimerism	Full: Both panels endorsed the existing definition of full donor chimerism as >95% for both myeloid and lymphoid lineages.
	Mixed or partial: Both panels endorsed the existing definition of mixed donor chimerism as 5%–95% for both myeloid and lymphoid lineages.
	Absent: Both panels endorsed the existing definition of absent donor chimerism as <5% for both myeloid and lymphoid lineages.

Note that delayed engraftment and primary graft failure after G-CSF-stimulated BM were not reviewed nor discussed as no previous consensus was reached in the referenced publication by Kharfan-Dabaja, ASTCT 2021 [17].

PBSC peripheral blood stem cells, ANC absolute neutrophil count, BM bone marrow cells, G-CSF granulocyte colony-stimulating factor.

*Donor chimerism testing is also done to confirm the suspicion of graft failure.

**Assumes that donor myeloid and lymphoid chimerism are within a desirable target level.